Pellet formulation for the treatment of the intestinal tract
AssigneeDr. Falk Pharma GmbH
InventorsNorbert Otterbeck, Peter Gruber
Life of this patent
Estimating the term…
Abstract
An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Claims21
An orally administrable pharmaceutical pellet formulation having a controlled release profile for the treatment of the intestinal tract, which comprises a core and an enteric coating, the core including aminosalicylic acid or a pharmaceutically acceptable salt thereof, wherein the aminosalicylic acid or pharmaceutically acceptable salt thereof is present in the core and homogenously dispersed in a non gel-forming polymer matrix which is essentially insoluble in the intestinal tract and permeable to intestinal fluids and the aminosalicylic acid, the matrix-forming polymer making up at least 1% and up to approximately 21% by weight of the total weight of the core.
An orally administrable pharmaceutical pellet formulation having a controlled release profile for the treatment of the intestinal tract, which comprises a core and an enteric coating, the core including aminosalicylic acid or a pharmaceutically acceptable salt thereof, wherein the aminosalicylic acid or pharmaceutically acceptable salt thereof is present in the core and homogenously dispersed in a polymer matrix which is essentially insoluble in the intestinal tract and permeable to intestinal fluids and the aminosalicylic acid, the matrix-forming polymer making up at least 1% and up to approximately 21% by weight of the total weight of the core.
An orally administrable pharmaceutical pellet formulation having a controlled release profile for the treatment of the intestinal tract, which comprises a core and an enteric coating, the core including aminosalicylic acid or a pharmaceutically acceptable salt thereof, wherein the aminosalicylic acid or pharmaceutically acceptable salt thereof is present in the core and homogenously dispersed in a polymer matrix which is essentially insoluble in the intestinal tract and permeable to intestinal fluids and the aminosalicylic acid, the matrix-forming polymer making up at least 1% by weight of the total weight of the core, and wherein the pellets have a size of 0.1 to 3 mm.
A controlled release pellet formulation for treatment of the intestinal tract, said formulation comprising:
- 1) a core comprising a homogeneously dispersed pharmaceutically active compound in a non gel-forming polymer matrix, and
- 2) an enteric coating,
- wherein the non gel-forming polymer matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluid made by the process comprising:
- mixing the pharmaceutically active compound and the non gel-forming polymer matrix;
- scattering in a pharmaceutically tolerable additive;
- and extruding a moist mass of the matrix-forming polymer and the active compound.
A controlled release pellet formulation for treatment of the intestinal tract, said formulation comprising:
- 1) a core comprising a homogeneously dispersed pharmaceutically active compound in a polymer matrix, and
- 2) an enteric coating,
- wherein the polymer matrix wherein the polymer is present in an amount which guarantees a delayed release of the aminosalicylic acid, is essentially insoluble in the intestinal tract and permeable to intestinal fluid made by the process comprising:
- mixing the pharmaceutically active compound and the non gel-forming polymer matrix;
- scattering in a pharmaceutically tolerable additive;
- and extruding a moist mass of the matrix-forming polymer and the active compound.
Dependencies are inferred from the claim text.